IndraLab

Statements

Ruxolitinib inhibits TYK2. 14 / 14
10 1 | 3
tas
No evidence text available
23668484
tas
No evidence text available
21106455
reach
"Ruxolitinib, which inhibits JAK2 but also TYK2, JAK1 and JAK3 XREF_BIBR at similar degrees demonstrated durable reduction in splenomegaly and constitutional symptoms with improved quality of life in comparison to placebo controlled XREF_BIBR or best available therapy XREF_BIBR in phase 3 trials and an impact on survival for patients originally randomized to ruxolitinib compared with those originally randomized to placebo in both COMFORT trials XREF_BIBR."
26176817
tas
No evidence text available
26927423
dgi
No evidence text available
tas
No evidence text available
22698084
tas
No evidence text available
24461299
tas
No evidence text available
24417533
tas
No evidence text available
22037378
reach
"Tofacitinib and ruxolitinib also inhibited all of the JAK enzymes, but the JAK3 inhibition by tofacitinib and JAK2 and Tyk2 inhibition by ruxolitinib were significantly more potent than those of JTE-052."
25387665
tas
No evidence text available
22591402
reach
"Ruxolitinib is claimed to be a specific inhibitor of the Janus kinases JAK1 and JAK2, but does not block JAK3 or TYK2, and we next determined whether knock down of JAK1 and JAK2 could account for the effects of ruxolitinib."
27379204
tas
No evidence text available
23061660
tas
No evidence text available
29298069